| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8230271 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 7 Pages |
Abstract
Gefitinib (250 mg daily) in combination with RT and CDDP in patients with Stage III NSCLC is feasible, but CDDP likely enhances toxicity. The impact of gefitinib on survival and disease control as a first-line treatment in combination with RT remains to be determined.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Sacha M.D., Stephan E. Ph.D., Jacques M.D., Daniel M. M.D., Aberrahim M.D., Gerhard M.D., Norbert M.D., Thomas M.D., Urs M. M.D., Christoph M.D., I. Frank M.D,